Clinical Trials Browser

Phase 1/2 × durvalumab × Gynecologic × Clear all

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02264678 2026-02-20

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1/2 Active not recruiting

357 enrolled

Gynecologic

Ovarian Neoplasms

NCT02726997 2025-12-18

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Phase 1/2 Active not recruiting

18 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04019288 2025-06-11

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03518606 2025-01-15

MOVIE

Phase 1/2 Completed

126 enrolled

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03323398 2024-07-31

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Phase 1/2 Terminated

79 enrolled 18 charts

GynecologicLymphoid

Lymphoma, Ovarian Neoplasms, Recurrence

NCT02291055 2023-03-20

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1/2 Terminated

75 enrolled 23 charts

GynecologicHead & Neck

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT02963831 2022-12-22

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Phase 1/2 Completed

67 enrolled 16 charts

GastrointestinalGynecologic

Appendiceal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02431559 2022-10-10

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

53 enrolled 22 charts

Gynecologic

Ovarian Neoplasms

Clinical Trials

MEDIOLA

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MOVIE

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer